DXCM DexCom Inc
Company Analysis
Latest News
🔴 DexCom is trading 4% down today with no clear catalyst identified
DexCom is trading 4.01% down now at $82.30, with no clear company-specific explanation identified for the October 21 decline. - The latest company coverage...
🟢 DexCom Surges 4.3% After Announcing CONNECT Trial Results Published in New England Journal of Medicine
DexCom is trading 4.37% higher at $87.12 following the company's announcement on October 14, 2026, that the CONNECT randomized trial results have been...
🟢 DexCom is trading 4.1% up in pre-market amid healthcare-sector strength
DexCom is trading at $86.92, up 4.14%, in a move that appears consistent with healthcare-sector strength as investors rotate toward defensive stocks amid...
DexCom Wins Strong-Buy Upgrade as Citi Names It a Top-Two Pick
On October 8, 2026, Barclays upgraded DexCom to strong-buy. Analysts have a consensus Buy rating on the company, with a consensus price target of $91.96. Citi...
🔴 DexCom is trading 4.06% down; reason remains unclear
DexCom is trading 4.06% lower at $83.37 on October 6, 2026; the reason for the decline remains unclear. - The company announced a new season of its Dexcom U...
DexCom's Data Breach Threat: Can a $86.95 Stock Weather a Hack That Could Expose Millions of Diabetes Patients?
Reports emerged this week that hacking group ShinyHunters has claimed DexCom as its latest target, threatening to publish allegedly stolen corporate data...
Dexcom faces ShinyHunters threat to leak alleged corporate data
ShinyHunters has listed medical device company Dexcom as a new victim on its dark web leak site. The group threatens to publish allegedly stolen corporate data...
🔴 DexCom is trading 28.25% down in after-hours trading with no confirmed company-specific catalyst
DexCom is trading 28.25% down at $64.24 after-hours on September 22, 2026, with no confirmed company-specific catalyst. - No confirmed September 22 earnings...
Dexcom Promotes CFO Jereme Sylvain to Expanded COO & CFO Role
Dexcom has promoted its Executive Vice President and Chief Financial Officer, Jereme Sylvain, to the expanded role of EVP, Chief Operating Officer and Chief...
🟢 DexCom is trading 7.91% up in after-hours trading as broad U.S. indexes gain
DexCom is trading 7.91% up at $89.60 after closing at $83.03 on September 11, 2026, with broad risk-on sentiment likely supporting the move. - No new...
🔴 DexCom falls 4.1% — Healthcare Stocks Fall as Insurance Crisis Deepens
With Healthcare (XLV) down 2.2%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector is experiencing a...
Multiple Major Institutions Announce Significant New Stakes in DexCom
Several major institutional investors disclosed significant new investments in DexCom, according to 13F filings with the SEC reported on August 27, 2026....
🔴 DexCom is trading 21.92% down in after-hours trading with no confirmed company-specific catalyst
DexCom is trading 21.92% down at $71.43 in after-hours trading after closing at $91.48 on August 13, 2026; no new earnings release, regulatory action, analyst...
🔴 DexCom is trading 15.86% down in after-hours trading after an unexplained decline
DexCom is trading 15.86% down at $76.40 after an unexplained after-hours decline following its $90.80 regular-session close on August 12, 2026. - No reliable...
🔴 DexCom is trading 4.4% down in after-hours trading amid unconfirmed trading activity
DexCom is trading at $85.59, down -4.40%, with the decline appearing driven by unconfirmed trading activity or profit-taking. - No clear company-specific...
🔴 DexCom is trading 4.49% down today without a clear company-specific catalyst
DexCom is trading 4.49% down at $83.04 following a sharp pullback from the prior session’s close of $86.94, likely reacting to normal post-rally volatility. •...
🟢 DexCom is trading 4.1% up today on record margin expansion and Type 2 market pivot
DexCom is trading 4.1% up at $86.85 as investors digest record margin expansion and a strategic pivot toward the large Type 2 diabetes market. • The move...
🟢 DexCom is trading 10.6% up today after Q2 earnings beat and raised full-year guidance
DexCom is trading 10.6% up today at $82.47 after reporting better-than-expected second quarter 2026 results and raising its full-year guidance. • The company...
🟢 DexCom is trading 6.1% up today after beating Q2 estimates and raising its 2026 outlook
DexCom is trading 6.1% up at $79.07 after reporting better-than-expected second quarter results and raising its full-year 2026 outlook. • Revenue grew 13%...
DexCom Delivers a Blowout Quarter and Bets Big on Type 2 Diabetes — But Can an $82 Stock Sustain This Momentum?
Shares of DexCom surged 10% to $82.00 in after-hours trading on July 30 after the glucose-monitor maker crushed second-quarter expectations and raised its...